[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]

Magy Onkol. 2010 Dec;54(4):369-76. doi: 10.1556/MOnkol.54.2010.4.11.
[Article in Hungarian]

Abstract

Recent advances in understanding the fundamental biology underlying clear-cell RCC have opened the door to a series of targeted agents, such as tyrosine kinase inhibitors (TKIs) or mTOR inhibitors. These new agents have become the standard of care in managing advanced clear-cell RCC. Choice of initial medical management in patients with metastatic clear-cell RCC should be guided by randomised studies. On the evidence available, the first-line therapy in patients with good- or intermediate-risk mRCC should be either sunitinib or pazopanib, or bevacizumab plus interferon. In selected patients sorafenib is an option, as is high-dose interleukin-2 if performance status is good. In patients with poor prognosis, temsirolimus is recommended. In cytokine refractory patients, sorafenib, when patients have progressed on a tyrosine kinase inhibitor everolimus is the agent of choice. Biró K, Küronya Z. Recent advancements in the treatment of renal cell carcinoma - focus on international guidelines.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / epidemiology
  • Carcinoma, Renal Cell / secondary
  • Clinical Trials as Topic
  • Europe / epidemiology
  • Humans
  • Immunotherapy / methods
  • Indazoles
  • Indoles / therapeutic use
  • Interferons / therapeutic use
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / epidemiology
  • Kidney Neoplasms / pathology
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use
  • Pyrroles / therapeutic use
  • Sulfonamides / therapeutic use
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Indazoles
  • Indoles
  • Interleukin-2
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Pyrroles
  • Sulfonamides
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • pazopanib
  • Interferons
  • MTOR protein, human
  • Protein-Tyrosine Kinases
  • TOR Serine-Threonine Kinases
  • Sunitinib